Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of artemisinin in prevention and treatment of cerebral apoplexy

A technique for artemisinin and stroke, applied in the application field of artemisinin in the prevention and treatment of stroke, can solve the problems of high incidence of stroke, lack of artemisinin, and high mortality, achieve low clinical side effects and reduce neurological deficits. Apoptosis and cell loss, the effect of improving nerve function

Inactive Publication Date: 2019-02-22
UNIVERSITY OF MACAU
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The incidence of stroke is high, the mortality rate is high, and the disability rate is high. At present, there is no safe and effective drug for the treatment of stroke
However, there is no relevant report on the relationship between artemisinin and stroke neuroprotection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of artemisinin in prevention and treatment of cerebral apoplexy
  • Application of artemisinin in prevention and treatment of cerebral apoplexy
  • Application of artemisinin in prevention and treatment of cerebral apoplexy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 Effect of Artemisinin on Neurological Function Evaluation of Cerebral Ischemia-Reperfusion Mice

[0040] Forty C57 / B6L mice were divided into 5 groups with 8 mice in each group. The body weight was weighed before administration, and the dosage was calculated according to the body weight. Group A is the blank control group (given with the same amount of normal saline); Group B is the model group (given with the same amount of normal saline); Group C is the model group + artemisinin 2 mg / kg; group D is the model group + artemisinin 6mg / kg; E group model group + artemisinin 18mg / kg. We used the middle cerebral artery occlusion method to create a mouse model of cerebral ischemia-reperfusion. After 1 hour of cerebral ischemia, the model mice were pulled out the thread plug, reperfused, and given different concentrations of artemisinin (2mg / kg, 6mg / kg and 18mg / kg) were administered intraperitoneally to middle cerebral artery occlusion model mice, and the neurolog...

Embodiment 2

[0043] Example 2: Artemisinin dose-dependent and time-dependent improvement of cerebral infarct size in mice with cerebral ischemia-reperfusion

[0044] Forty C57 / B6L mice were divided into 5 groups with 8 mice in each group. The body weight was weighed before administration, and the dosage was calculated according to the body weight. Group A is the blank control group (given with the same amount of normal saline); Group B is the model group (given with the same amount of normal saline); Group C is the model group + artemisinin 2 mg / kg; group D is the model group + artemisinin 6mg / kg; E group model group + artemisinin 18mg / kg. First, we used the middle cerebral artery occlusion method to create a mouse cerebral ischemia-reperfusion model. After 1 hour of cerebral ischemia in the middle cerebral artery occlusion model mouse, the thread plug was pulled out for reperfusion. When measuring dose-dependent cerebral infarct size, artemisinin (2mg / kg, 6mg / kg and 18mg / kg) of differen...

Embodiment 3

[0046] Example 3: Effect of Artemisinin on Cerebral Edema in Cerebral Ischemia-Reperfusion Mice

[0047] Forty C57 / B6L mice were divided into 5 groups with 8 mice in each group. The body weight was weighed before administration, and the dosage was calculated according to the body weight. Group A is the blank control group (given with the same amount of normal saline); Group B is the model group (given with the same amount of normal saline); Group C is the model group + artemisinin 2 mg / kg; group D is the model group + artemisinin 6mg / kg; E group model group + artemisinin 18mg / kg. First, we used the middle cerebral artery occlusion method to make a mouse cerebral ischemia-reperfusion model. After 1 hour of cerebral ischemia, the thread plug was pulled out and reperfusion was performed. At the same time, different concentrations of artemisinin (2mg / kg, 6mg / kg , 18mg / kg) were administered to mice by intraperitoneal injection, and the water content in the brain was measured by d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of artemisinin in the prevention and treatment of cerebral apoplexy. Artemisinin is low in side effect, and the neurological functions of an ischemic mouse witha cerebral ischemia reperfusion symptom are improved by activating an ERK1 / 2 signal channel in the brain of the mouse; and the encephaledema and oxidative damage of the ischemic mouse with the cerebral ischemia reperfusion symptom are relieved, the cerebral infarction area of the mouse with the cerebral ischemia reperfusion symptom is reduced, and the nerve cell apoptosis, loss and the like of themouse with the cerebral ischemia reperfusion symptom are reduced, so that artemisinin has positive effects on the improvement of cerebral apoplexy.

Description

technical field [0001] The invention relates to the application field of traditional Chinese medicine monomers, in particular to the application of artemisinin in the prevention and treatment of stroke. Background technique [0002] At present, stroke is the first cause of death in my country and the leading cause of adult disability. The morbidity, mortality and disability of stroke are high, and there is no safe and effective drug for the treatment of stroke. [0003] The oxidation state of TTC (2,3,5-triphenyltetrazolium chloride) is colorless and can be reduced by hydrogen to the insoluble red trityl trityl (TTF). Soak the brain tissue in an aqueous solution of TTC so that it penetrates into the cells of the brain tissue. If the cells have vitality, the dehydrogenase in them can use TTC as a hydrogen acceptor to reduce it to trityl and turn red (normal brain Tissue is stained red), or pale if it is an infarcted area. The calculation formula of Belayev et al was used t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/366A61P9/10A61P7/10
CPCA61K31/366A61P7/10A61P9/10
Inventor 郑文华彭汤明
Owner UNIVERSITY OF MACAU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com